Article Details
Retrieved on: 2024-12-09 00:04:18
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
Roche (RHHBY) announced data from a five-year follow-up of the pivotal Phase 3 POLARIX study evaluating Polivy in combination with MabThera/Ritu.
Article found on: markets.businessinsider.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here